Idorsia rolls out insomnia med Quviviq with sales team, digital marketing and DTC in the works – Endpoints News


Idorsia hit the marketing ground running with its insomnia launch, debuting an awareness campaign starring popular “Friends” actress Jennifer Aniston just days after its Quviviq approval in January. Now the insomnia brand hit shelves this week with a sales force rollout to physicians, digital and social media ads and plans for a direct-to-consumer campaign coming soon.
A field team of about 500 sales reps plus another 100 customer-facing medical affairs, market access and others are reaching out to physicians in the first wave of Quviviq marketing, said Patricia Torr, president and general manager of Idorsia US. About 75% of the target group of doctors are primary care, with psychiatry and a few other specialties making up the rest.
Unlock this story instantly and join 141,300+ biopharma pros reading Endpoints daily — and it’s free.
Gene therapies hold huge promise for patients with a range of monogenic diseases and unmet medical needs. However, they’ve had their fair share of safety concerns – dosing and delivery have been the sources of recent setbacks. Efficient, scalable, and cost-effective manufacturing is another hurdle the industry needs to overcome before commercially viable therapies can be licensed. AAV technology advances are also needed to address yield, material costs, and cycle times in a bid to bring down COGS and ultimately increase financial accessibility by global patient populations.
Johnson & Johnson Health Care Systems is suing a New Jersey middleman to stop it from increasing drug costs for patients.
According to the lawsuit, the action is intended to stop SaveOnSP from conducting a scheme to pilfer tens of millions of dollars from the financial support program that J&J Healthcare Services provides for patients.
SaveOnSP, based in New York state, runs a co-pay adjustment strategy that intends to build on existing insurer-driven co-pay adjustment programs. The program is run in partnership with PBM Express Scripts and operated in conjunction with specialty pharmacy Accredo.
Pharma marketers are finally starting to diversify the advertising media mix, a new study finds, but don’t count on any abrupt shifts away from tried-and-true TV.
Veeva Crossix’s health advertising report finds that while pharma advertisers are beginning to adopt streaming TV media, traditional TV budgets are still 8 times higher. Still, it is growing — pharma increased spending by 34% on streaming TV advertising over the past year.
Unlock this story instantly and join 141,300+ biopharma pros reading Endpoints daily — and it’s free.
Pharmacy benefit managers ⁠— the much-maligned middlemen of the pharmaceutical supply chain ⁠— took the brunt of questioning from senators on both sides of the aisle on Thursday at a commerce committee hearing.
Echoing recent and similar questions from the FTC, front and center at the Senate hearing were the anti-competitive practices of PBMs, like artificially inflating the list prices of certain drugs while collecting a growing portion of rebates, and increasing out-of-pocket costs for consumers along the way.
After finding some quality issues attributed to its manufacturing process, Novartis has halted the production of two of its radioligand therapies at sites in Italy and New Jersey, the company announced Thursday.
The production of Lutathera and Pluvicto will stop temporarily at its sites in Ivrea, Italy and Millburn, NJ. The moves come out of “an abundance of caution” after some quality issues were identified. Production is expected to resume within the next six weeks, Novartis said.
AstraZeneca caught a trio of recent wins — scoring an expanded indication for its breast cancer drug Enhertu, nailing Farxiga’s Phase III win earlier this week, and now, another trial win.
The UK pharma said Thursday that its long-acting C5 complement inhibitor drug Ultomiris (ravulizumab-cwvz) hit on its primary endpoint in the Phase III CHAMPION-NMOSD study. That endpoint was to show a “statistically significant and clinically meaningful reduction in the risk of relapse in adults” with a specific type of a rare autoimmune disease that targets the central nervous system.
After receiving complaints from the SEC last spring, Biogen changed the way it reports upfront payments to collaborators in its quarterly updates. But it appears Biogen wasn’t the only one who got the message.
Several pharma giants — including Eli Lilly, Merck, Bristol Myers Squibb, AbbVie and Pfizer — are making similar changes in this year’s Q1 results, according to Market Watch, which first reported the news. The changes revolve around certain figures that don’t comply with Generally Accepted Accounting Principles, also known as non-GAAP measures.
Intercept Pharmaceuticals, the biotech that brought NASH to the forefront of drug development R&D, has sold off the ex-US rights to its autoimmune disease drug Ocaliva as the company prepares the same med for another shot at the disease. And with the biotech on tap for a pre-submission meeting with the FDA this year in NASH, execs now have additional funds to bankroll that work.
European specialty pharma brand Advanz is dishing out $405 million upfront and up to $45 million more to gain the ex-US rights to Ocaliva, most of Intercept’s international operations and certain subsidiaries, the company said Thursday. Taken together, that’s about the same figure as Intercept’s cash on hand at the end of 2021: $429.4 million.
Unlock this story instantly and join 141,300+ biopharma pros reading Endpoints daily — and it’s free.
With new technology comes the challenges of regulating it. And with the ever-growing faith being poured into mRNA technology the FDA has found itself training new investigators for more inspections going forward.
Investigators will learn about specifics related to Covid-19, influenza, combination and cancer vaccines, as well as the application of testing methods specific to mRNA and the special consideration of contamination control, a recent notice from the FDA says. Training sessions will include on-demand recordings and modules, as well as experiential training through access to a facility or laboratory with medical product manufacturing. Augmented reality and virtual reality will also be included.
Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas<!–
2029 Becker Drive,
(785) 813-1733 –>
© Endpoints Company 2022
If you’re already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We’ll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.